Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07009860
PHASE2

RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

Sponsor: Altimmune, Inc.

View on ClinicalTrials.gov

Summary

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD. * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly

Official title: RESTORE TRIAL: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2025-06-16

Completion Date

2027-08-31

Last Updated

2026-03-20

Healthy Volunteers

No

Interventions

DRUG

Pemvidutide

Pemvidutide 2.4 mg

OTHER

Placebo

Subcutaneous injection

Locations (43)

Altimmune Clinical Study Site

Peoria, Arizona, United States

Altimmune Clinical Study Site

Tucson, Arizona, United States

Altimmune Clinical Study Site

Tuscon, Arizona, United States

Altimmune Clinical Study Site

North Little Rock, Arkansas, United States

Altimmune Clinical Study Site

Fresno, California, United States

Altimmune Clinical Study Site

La Jolla, California, United States

Altimmune Clinical Study Site

Pasadena, California, United States

Altimmune Clinical Study Site

Englewood, Colorado, United States

Altimmune Clinical Study Site

Bradenton, Florida, United States

Altimmune Clinical Study Site

Doral, Florida, United States

Altimmune Clinical Study Site

Doral, Florida, United States

Altimmune Clinical Study Site

Fort Myers, Florida, United States

Altimmune Clinical Study Site

Miami, Florida, United States

Altimmune Clinical Study Site

Miami, Florida, United States

Altimmune Clinical Study Site

Miami Lakes, Florida, United States

Altimmune Clinical Study Site

Naples, Florida, United States

Altimmune Clinical Study Site

Orlando, Florida, United States

Altimmune Clinical Study Site

Port Orange, Florida, United States

Altimmune Clinical Study Site

Atlanta, Georgia, United States

Altimmune Clinical Study Site

Indianapolis, Indiana, United States

Altimmune Clinical Study Site

Louisville, Kentucky, United States

Altimmune Clinical Study Site

Bastrop, Louisiana, United States

Altimmune Clinical Study Site

Marrero, Louisiana, United States

Altimmune Clinical Study Site

West Monroe, Louisiana, United States

Altimmune Clinical Study Site

Kansas City, Missouri, United States

Altimmune Clinical Study Site

St Louis, Missouri, United States

Altimmune Clinical Study Site

Las Vegas, Nevada, United States

Altimmune Clinical Study Site

Manhasset, New York, United States

Altimmune Clinical Study Site

New York, New York, United States

Altimmune Clinical Study Site

Syracuse, New York, United States

Altimmune Clinical Study Site

Wilmington, North Carolina, United States

Altimmune Clinical Study Site

Westlake, Ohio, United States

Altimmune Clinical Study Site

Brownsville, Texas, United States

Altimmune Clinical Study Site

Dallas, Texas, United States

Altimmune Clinical Study Site

Edinburg, Texas, United States

Altimmune Clinical Study Site

Houston, Texas, United States

Altimmune Clinical Study Site

Houston, Texas, United States

Altimmune Clinical Study Site

San Antonio, Texas, United States

Altimmune Clinical Study Site

San Antonio, Texas, United States

Altimmune Clinical Study Site

Waco, Texas, United States

Altimmune Clinical Study Site

Richmond, Virginia, United States

Altimmune Clinical Study Site

Seattle, Washington, United States

Altimmune Clinical Study Site

San Juan, Puerto Rico, Puerto Rico